Apyx Medical Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Apyx Medical de 25% y 12.5% respectivamente, mientras que el BPA crecerá en un 26.1% al año.

Información clave

25.0%

Tasa de crecimiento de los beneficios

24.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.6%
Tasa de crecimiento de los ingresos	12.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	09 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apr 18

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Mar 26

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Feb 16

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Sep 14

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Jun 07

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Mar 21

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Dec 14

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Aug 30

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Aug 11

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Jul 18

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:APYX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	63	-17	-6	N/A	3
12/31/2025	55	-24	-24	N/A	5
12/31/2024	50	-26	-23	N/A	5
3/31/2024	50	-23	N/A	N/A	N/A
12/31/2023	52	-19	-6	-5	N/A
9/30/2023	50	-15	-8	-8	N/A
6/30/2023	47	-16	-17	-17	N/A
3/31/2023	44	-21	-18	-18	N/A
12/31/2022	45	-23	-21	-20	N/A
9/30/2022	49	-19	-17	-16	N/A
6/30/2022	51	-18	-15	-14	N/A
3/31/2022	52	-16	-14	-13	N/A
12/31/2021	49	-15	-11	-10	N/A
9/30/2021	43	-15	-12	-12	N/A
6/30/2021	38	-14	-11	-11	N/A
3/31/2021	31	-15	-11	-11	N/A
12/31/2020	28	-12	-17	-16	N/A
9/30/2020	25	-16	-19	-18	N/A
6/30/2020	25	-16	-21	-20	N/A
3/31/2020	28	-16	-22	-21	N/A
12/31/2019	28	-20	-20	-18	N/A
9/30/2019	26	-18	-35	-33	N/A
6/30/2019	22	-15	-30	-30	N/A
3/31/2019	19	-14	-25	-25	N/A
12/31/2018	17	-11	-21	-21	N/A
9/30/2018	14	-10	-2	-2	N/A
6/30/2018	13	-12	-2	-1	N/A
3/31/2018	5	-15	-3	-2	N/A
12/31/2017	10	-14	N/A	-4	N/A
9/30/2017	-12	-19	N/A	-5	N/A
6/30/2017	-4	-17	N/A	-4	N/A
3/31/2017	37	-4	N/A	-3	N/A
12/31/2016	9	-12	N/A	-3	N/A
9/30/2016	35	-5	N/A	-3	N/A
6/30/2016	33	-5	N/A	-4	N/A
3/31/2016	31	-6	N/A	-6	N/A
12/31/2015	30	8	N/A	-6	N/A
9/30/2015	29	4	N/A	-5	N/A
6/30/2015	28	3	N/A	-3	N/A
3/31/2015	27	4	N/A	-1	N/A
12/31/2014	28	-18	N/A	0	N/A
9/30/2014	26	-18	N/A	-2	N/A
6/30/2014	25	-15	N/A	-3	N/A
3/31/2014	24	-16	N/A	-3	N/A
12/31/2013	24	-7	N/A	-3	N/A
9/30/2013	24	-2	N/A	-1	N/A
6/30/2013	25	-1	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que APYX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que APYX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que APYX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (12.8% al año) de APYX crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.8% al año) de APYX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de APYX se prevé que sea elevada dentro de 3 años.

Apyx Medical Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

Consensus revenue estimates fall by 17%

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Consensus revenue estimates fall by 11%

Price target increased by 16% to US$9.00

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

New major risk - Revenue and earnings growth

Apyx Medical Corporation to Report Q1, 2024 Results on May 09, 2024

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Consensus revenue estimates fall by 17%

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Apyx Medical Corporation to Report Q4, 2023 Results on Mar 21, 2024

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

New major risk - Revenue and earnings growth

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

New major risk - Share price stability

President recently bought US$79k worth of stock

Consensus revenue estimates fall by 11%

Apyx Medical Corporation announced that it expects to receive $45 million in funding

Price target increased by 16% to US$9.00

New minor risk - Market cap size

Apyx Medical Corporation to Report Q3, 2023 Results on Nov 09, 2023

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Apyx Medical Corporation Reaffirms Financial Guidance for the Year Ending December 31, 2023

New major risk - Share price stability

Executive Vice President exercised options and sold US$87k worth of stock

Apyx Medical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Executive Vice President notifies of intention to sell stock

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 15%

Price target increased by 33% to US$8.00

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Full year 2022 earnings: EPS misses analyst expectations

Apyx Medical Corporation to Report Q4, 2022 Results on Mar 16, 2023

Apyx Medical Corporation Announces FDA 510(K) Submission for the Use of the Renuvion® Apr. Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

Apyx Medical Corporation Launches New 'Apyx One Console' for Cosmetic Surgical Procedures in the United States

Apyx Medical Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Consensus revenue estimates fall by 15%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Price target decreased to US$10.33

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

President recently bought US$70k worth of stock

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Price target increased to US$14.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Apyx Medical Corporation Updates Earnings Guidance for the Full Year Ending December 31, 2022

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Price target increased to US$12.50

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Lead Independent Director exercised options to buy US$150k worth of stock.

Apyx Medical Corporation Announces Results of the U.S. Ide Clinical Study Evaluating the Use of Renuvion to Improve the Appearance of Lax Skin in the Neck and Submental Region

Apyx Medical Corporation to Report Q2, 2022 Results on Aug 11, 2022

Apyx Medical Corporation Announces Receipt of 510(K) Clearance from FDA for Use of the Renuvion Dermal Handpiece for Specific Dermatological Procedures for Treatment of Moderate to Severe Wrinkles and Rhytides, Limited to Patients with Fitzpatrick Skin Types I, II or III

Apyx Medical Corporation(NasdaqGS:APYX) dropped from Russell 3000E Growth Index

Apyx Medical Corporation, Annual General Meeting, Aug 11, 2022